Xi Wang

Xi Wang

Auto-generated profile, based on publicly available information

Xi Wang

Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Peking University, Beijing, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2019 in Nature Communications
Verified
Journal Article
Open access
QLQingsheng Liu
Qingsheng Liu
ACAlan Chiu
Alan Chiu
LWLong-Hai Wang
Long-Hai Wang
DADuo An
Duo An
MZMonica Zhong
Monica Zhong
MMMinglin Ma
Minglin Ma
Foreign body reaction (FBR) to implanted biomaterials and medical devices is common and can compromise the function of implants or cause complications. For example, in cell encapsulation, cellular overgrowth (CO) and fibrosis around the cellular constructs can reduce the mass transfer of oxygen, nutrients and metabolic wastes, undermining cell function and leading to transplant failure. Therefore, materials that mitigate FBR or CO will have broad applications in biomedicine. Here we report a group of zwitterionic, sulfobetaine (SB) and carboxybetaine (CB) modifications of alginates that reproducibly mitigate the CO of implanted alginate microcapsules in mice, dogs and pigs. Using the modified alginates (SB-alginates), we also demonstrate improved outcome of islet encapsulation in a chemically-induced diabetic mouse model. These zwitterion-modified alginates may contribute to the development of cell encapsulation therapies for type 1 diabetes and other hormone-deficient diseases.

24 July 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
KWKai Wang
Kai Wang
RLRuei-Zeng Lin
Ruei-Zeng Lin
XHXuechong Hong
Xuechong Hong
ANAlex H. Ng
Alex H. Ng
CLChin Nien Lee
Chin Nien Lee
JMJuan M. Melero-Martin
Juan M. Melero-Martin
Human induced pluripotent stem cell (h-iPSC)–derived endothelial cells (h-iECs) have become a valuable tool in regenerative medicine. However, current differentiation protocols remain inefficient and lack reliability. Here, we describe a method for rapid, consistent, and highly efficient generation of h-iECs. The protocol entails the delivery of modified mRNA encoding the transcription factor ETV2 at the intermediate mesodermal stage of differentiation. This approach reproducibly differentiated 13 diverse h-iPSC lines into h-iECs with exceedingly high efficiency. In contrast, standard differentiation methods that relied on endogenous ETV2 were inefficient and notably inconsistent. Our h-iECs were functionally competent in many respects, including the ability to form perfused vascular networks in vivo. Timely activation of ETV2 was critical, and bypassing the mesodermal stage produced putative h-iECs with reduced expansion potential and inability to form functional vessels. Our protocol has broad applications and could reliably provide an unlimited number of h-iECs for vascular therapies.

2 June 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
XWXi Wang
Xi Wang
KMKristina G. Maxwell
Kristina G. Maxwell
KWKai Wang
Kai Wang
DBDaniel T. Bowers
Daniel T. Bowers
JFJames A. Flanders
James A. Flanders
MMMinglin Ma
Minglin Ma
A nanofibrous cell encapsulation device containing rodent/human islets or human stem cell–derived β cells treats diabetes in rodents.

10 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
WSWei Song
Wei Song
ACAlan Chiu
Alan Chiu
LWLong-Hai Wang
Long-Hai Wang
RSRobert E. Schwartz
Robert E. Schwartz
BLBin Li
Bin Li
MMMinglin Ma
Minglin Ma
The success of engineered cell or tissue implants is dependent on vascular regeneration to meet adequate metabolic requirements. However, development of a broadly applicable strategy for stable and functional vascularization has remained challenging. We report here highly organized and resilient microvascular meshes fabricated through a controllable anchored self-assembly method. The microvascular meshes are scalable to centimeters, almost free of defects and transferrable to diverse substrates, ready for transplantation. They promote formation of functional blood vessels, with a density as high as ~220 vessels mm-2, in the poorly vascularized subcutaneous space of SCID-Beige mice. We further demonstrate the feasibility of fabricating microvascular meshes from human induced pluripotent stem cell-derived endothelial cells, opening a way to engineer patient-specific microvasculature. As a proof-of-concept for type 1 diabetes treatment, we combine microvascular meshes and subcutaneously transplanted rat islets and achieve correction of chemically induced diabetes in SCID-Beige mice for 3 months.

14 May 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
LWLong-Hai Wang
Long-Hai Wang
AEAlexander Ulrich Ernst
Alexander Ulrich Ernst
JFJames Arthur Flanders
James Arthur Flanders
Wanjun LiuWanjun Liu
Wanjun Liu
XWXi Wang
Xi Wang
MMMinglin Ma
Minglin Ma
Cell encapsulation represents a promising therapeutic strategy for many hormone-deficient diseases such as type 1 diabetes (T1D). However, adequate oxygenation of the encapsulated cells remains a challenge, especially in the poorly oxygenated subcutaneous site. Here, we present an encapsulation system that generates oxygen (O2) for the cells from their own waste product, carbon dioxide (CO2), in a self-regulated (i.e., “inverse breathing”) way. We leveraged a gas-solid (CO2–lithium peroxide) reaction that was completely separated from the aqueous cellular environment by a gas permeable membrane. O2 measurements and imaging validated CO2-responsive O2 release, which improved cell survival in hypoxic conditions. Simulation-guided optimization yielded a device that restored normoglycemia of immunocompetent diabetic mice for over 3 months. Furthermore, functional islets were observed in scaled-up device implants in minipigs retrieved after 2 months. This inverse breathing device provides a potential system to support long-term cell function in the clinically attractive subcutaneous site.

1 September 2016 in Biomaterials
Verified
Journal Article
Closed access
KWKai Wang
Kai Wang
WHWen-Da Hou
Wen-Da Hou
XWXi Wang
Xi Wang
CHChengsheng Han
Chengsheng Han
IVIvan Vuletic
Ivan Vuletic
YLYing Luo
Ying Luo